Cerebral rituximab uptake in multiple sclerosis: A (89)Zr-immunoPET pilot study

Previous studies have demonstrated that the chimeric monoclonal antibody rituximab significantly reduces clinical and radiological disease activity in relapsing-remitting multiple sclerosis as early as 4 weeks after the first administration. The exact mechanisms leading to this rapid effect have not...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagens, Marloes HJ, Killestein, Joep, Yaqub, Maqsood M, van Dongen, Guus AMS, Lammertsma, Adriaan A, Barkhof, Frederik, van Berckel, Bart NM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891689/
https://www.ncbi.nlm.nih.gov/pubmed/28443358
http://dx.doi.org/10.1177/1352458517704507
_version_ 1783313043203031040
author Hagens, Marloes HJ
Killestein, Joep
Yaqub, Maqsood M
van Dongen, Guus AMS
Lammertsma, Adriaan A
Barkhof, Frederik
van Berckel, Bart NM
author_facet Hagens, Marloes HJ
Killestein, Joep
Yaqub, Maqsood M
van Dongen, Guus AMS
Lammertsma, Adriaan A
Barkhof, Frederik
van Berckel, Bart NM
author_sort Hagens, Marloes HJ
collection PubMed
description Previous studies have demonstrated that the chimeric monoclonal antibody rituximab significantly reduces clinical and radiological disease activity in relapsing-remitting multiple sclerosis as early as 4 weeks after the first administration. The exact mechanisms leading to this rapid effect have not yet been clarified. The aim of this positron emission tomography study was to assess central nervous system penetration as a possible explanation, using zirconium-89-labelled rituximab. No evidence was found for cerebral penetration of [(89)Zr]rituximab.
format Online
Article
Text
id pubmed-5891689
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-58916892018-04-13 Cerebral rituximab uptake in multiple sclerosis: A (89)Zr-immunoPET pilot study Hagens, Marloes HJ Killestein, Joep Yaqub, Maqsood M van Dongen, Guus AMS Lammertsma, Adriaan A Barkhof, Frederik van Berckel, Bart NM Mult Scler Short Reports Previous studies have demonstrated that the chimeric monoclonal antibody rituximab significantly reduces clinical and radiological disease activity in relapsing-remitting multiple sclerosis as early as 4 weeks after the first administration. The exact mechanisms leading to this rapid effect have not yet been clarified. The aim of this positron emission tomography study was to assess central nervous system penetration as a possible explanation, using zirconium-89-labelled rituximab. No evidence was found for cerebral penetration of [(89)Zr]rituximab. SAGE Publications 2017-04-26 2018-04 /pmc/articles/PMC5891689/ /pubmed/28443358 http://dx.doi.org/10.1177/1352458517704507 Text en © The Author(s), 2017 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (http://www.uk.sagepub.com/aboutus/openaccess.htm).
spellingShingle Short Reports
Hagens, Marloes HJ
Killestein, Joep
Yaqub, Maqsood M
van Dongen, Guus AMS
Lammertsma, Adriaan A
Barkhof, Frederik
van Berckel, Bart NM
Cerebral rituximab uptake in multiple sclerosis: A (89)Zr-immunoPET pilot study
title Cerebral rituximab uptake in multiple sclerosis: A (89)Zr-immunoPET pilot study
title_full Cerebral rituximab uptake in multiple sclerosis: A (89)Zr-immunoPET pilot study
title_fullStr Cerebral rituximab uptake in multiple sclerosis: A (89)Zr-immunoPET pilot study
title_full_unstemmed Cerebral rituximab uptake in multiple sclerosis: A (89)Zr-immunoPET pilot study
title_short Cerebral rituximab uptake in multiple sclerosis: A (89)Zr-immunoPET pilot study
title_sort cerebral rituximab uptake in multiple sclerosis: a (89)zr-immunopet pilot study
topic Short Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891689/
https://www.ncbi.nlm.nih.gov/pubmed/28443358
http://dx.doi.org/10.1177/1352458517704507
work_keys_str_mv AT hagensmarloeshj cerebralrituximabuptakeinmultiplesclerosisa89zrimmunopetpilotstudy
AT killesteinjoep cerebralrituximabuptakeinmultiplesclerosisa89zrimmunopetpilotstudy
AT yaqubmaqsoodm cerebralrituximabuptakeinmultiplesclerosisa89zrimmunopetpilotstudy
AT vandongenguusams cerebralrituximabuptakeinmultiplesclerosisa89zrimmunopetpilotstudy
AT lammertsmaadriaana cerebralrituximabuptakeinmultiplesclerosisa89zrimmunopetpilotstudy
AT barkhoffrederik cerebralrituximabuptakeinmultiplesclerosisa89zrimmunopetpilotstudy
AT vanberckelbartnm cerebralrituximabuptakeinmultiplesclerosisa89zrimmunopetpilotstudy

Ejemplares similares